| Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML AE Perl, G Martinelli, JE Cortes, A Neubauer, E Berman, S Paolini, ... New England Journal of Medicine 381 (18), 1728-1740, 2019 | 1028 | 2019 |
| Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study AE Perl, JK Altman, J Cortes, C Smith, M Litzow, MR Baer, D Claxton, ... The Lancet Oncology 18 (8), 1061-1075, 2017 | 510 | 2017 |
| Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells W Fiskus, Y Wang, A Sreekumar, KM Buckley, H Shi, A Jillella, C Ustun, ... Blood, The Journal of the American Society of Hematology 114 (13), 2733-2743, 2009 | 420 | 2009 |
| First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation R Romee, S Cooley, MM Berrien-Elliott, P Westervelt, MR Verneris, ... Blood, The Journal of the American Society of Hematology 131 (23), 2515-2527, 2018 | 350 | 2018 |
| Advances in the classification and treatment of mastocytosis: current status and outlook toward the future P Valent, C Akin, K Hartmann, G Nilsson, A Reiter, O Hermine, K Sotlar, ... Cancer research 77 (6), 1261-1270, 2017 | 272 | 2017 |
| Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis SA Buckley, BL Wood, M Othus, CS Hourigan, C Ustun, MA Linden, ... haematologica 102 (5), 865, 2017 | 255 | 2017 |
| Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia DL DeRemer, C Ustun, K Natarajan Clinical therapeutics 30 (11), 1956-1975, 2008 | 230 | 2008 |
| Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? C Ustun, JS Miller, DH Munn, DJ Weisdorf, BR Blazar Blood, The Journal of the American Society of Hematology 118 (19), 5084-5095, 2011 | 215 | 2011 |
| Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative … Y Wang, W Fiskus, DG Chong, KM Buckley, K Natarajan, R Rao, A Joshi, ... Blood, The Journal of the American Society of Hematology 114 (24), 5024-5033, 2009 | 193 | 2009 |
| Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI EA Copelan, BK Hamilton, B Avalos, KW Ahn, BJ Bolwell, X Zhu, M Aljurf, ... Blood, The Journal of the American Society of Hematology 122 (24), 3863-3870, 2013 | 187 | 2013 |
| Hematopoietic stem-cell transplantation for advanced systemic mastocytosis C Ustun, A Reiter, BL Scott, R Nakamura, G Damaj, S Kreil, R Shanley, ... Journal of Clinical Oncology 32 (29), 3264, 2014 | 181 | 2014 |
| Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal P Valent, C Akin, K Hartmann, I Alvarez-Twose, K Brockow, O Hermine, ... Hemasphere 5 (11), e646, 2021 | 166 | 2021 |
| Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant … V Gupta, AK Malone, PN Hari, KW Ahn, ZH Hu, RP Gale, KK Ballen, ... Biology of Blood and Marrow Transplantation 20 (1), 89-97, 2014 | 155 | 2014 |
| Tyrosine kinase inhibitors in the treatment of systemic mastocytosis C Ustun, DL DeRemer, C Akin Leukemia research 35 (9), 1143-1152, 2011 | 153 | 2011 |
| Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation J Vydra, RM Shanley, I George, C Ustun, AR Smith, DJ Weisdorf, ... Clinical Infectious Diseases 55 (6), 764-770, 2012 | 151 | 2012 |
| Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1 R Balusu, W Fiskus, R Rao, DG Chong, S Nalluri, U Mudunuru, H Ma, ... Blood, The Journal of the American Society of Hematology 118 (11), 3096-3106, 2011 | 144 | 2011 |
| Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal P Valent, K Sotlar, WR Sperr, L Escribano, S Yavuz, A Reiter, TI George, ... Annals of oncology 25 (9), 1691-1700, 2014 | 139 | 2014 |
| Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts P Valent, C Akin, K Hartmann, G Nilsson, A Reiter, O Hermine, K Sotlar, ... Theranostics 10 (23), 10743, 2020 | 132 | 2020 |
| Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival LE Lunde, S Dasaraju, Q Cao, CS Cohn, M Reding, N Bejanyan, ... Bone marrow transplantation 50 (11), 1432-1437, 2015 | 131 | 2015 |
| Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis C Ustun, J Gotlib, U Popat, A Artz, M Litzow, A Reiter, R Nakamura, ... Biology of Blood and Marrow Transplantation 22 (8), 1348-1356, 2016 | 102 | 2016 |
